How much Celltrion’s ‘Remsima’ is prescribed in Europe?

It was observed the collective number of patients prescribed for the Celltrion’s autoimmune disease treatment ‘Remsima(U.S. Johnson & Johnson’s ‘Remicade’ biosimilar)’ is about 100 thousand, accounting for approximately 40% of the European infliximab(substance of ‘Remicade’) market.

By country, it has taken more than 90% of the market in countries having the governmental bidding system, such ...